Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome" [Multiple Sclerosis and Related Disorders 112 (2026) 107312].

Multiple sclerosis and related disorders·2026

Same author

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026

Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026

Same author

A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome.

Multiple sclerosis and related disorders·2026

Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.

Neurology and therapy·2026

Search research articles

Related Experiment Video

Updated: Jun 26, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Association Between Disease-Modifying Therapy and Information Processing Speed in Multiple Sclerosis.

Albert Aboseif¹, Moein Amin², James Bena¹

¹From the Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

International Journal of MS Care

|May 20, 2024

Summary

This summary is machine-generated.

Disease-modifying therapy (DMT) use and intensity did not significantly impact cognitive processing speed in multiple sclerosis (MS) patients over two years. Further research is needed to confirm these findings on cognitive function in MS.

Keywords:

cognitive impairment disease-modifying therapy multiple sclerosis processing speed

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 26, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

Neurology
Neuroimmunology
Cognitive Neuroscience

Background:

Cognitive impairment is a prevalent issue in multiple sclerosis (MS).
Processing speed (PS) deficits are common in MS and serve as a key indicator for cognitive impairment.
Evaluating the impact of disease-modifying therapies (DMTs) on cognitive function is crucial for MS management.

Purpose of the Study:

To investigate the association between disease-modifying therapy (DMT) use and its intensity with longitudinal changes in processing speed.
To assess if DMT status (on vs. off therapy) and efficacy (high vs. low/moderate) influence cognitive processing speed over time in individuals with MS.

Main Methods:

Retrospective analysis of Processing Speed Test (PST) scores from individuals with at least two assessments.
Comparison of longitudinal PST scores between patients on DMTs for over two years and those off DMTs for over two years.
Propensity score adjustment using multivariable logistic regression to control for confounding factors.

Main Results:

The study included 642 individuals: 539 on DMT and 103 off DMT.
After adjusting for multiple factors, neither DMT status nor intensity significantly predicted longitudinal changes in PST scores.
The average monitoring duration was approximately 1.8-1.9 years for both DMT and non-DMT groups.

Conclusions:

DMT status and intensity were not significant predictors of cognitive processing speed over a two-year period.
These findings suggest that current DMTs may not substantially alter cognitive processing speed trajectories in MS.
Prospective studies are recommended to further validate these results and explore other factors influencing cognitive function in MS.